Research Project

研究项目

基本信息

批准号：
8033909
负责人：
Christi A Patten
金额：
$ 55.4万
依托单位：
MAYO CLINIC ROCHESTER
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-07-01 至 2015-07-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8033909
关键词：
Abstinence Advisory Committees Alaska Native American Indian and Alaska Native Arctic Regions Biological Markers Birth Blood specimen Butanones Cancer Etiology Carcinogen exposure Carcinogens Cause of Death Centers for Disease Control and Prevention (U.S.)Cessation of life Cigarette Smoker Clinic Clinical Communities Cotinine Doctor of Philosophy Enrollment Evaluation Exposure to Feedback Future Health Individual Infant Intervention Interview Investigation Malignant Neoplasms Malignant neoplasm of lung Medical center Mothers Native-Born Neonatal Nicotine Nitrosamines Participant Phase Pilot Projects Pregnancy Pregnant Women Prevalence Public Health Randomized Research Project Grants Risk Sampling Smoke Smokeless Tobacco Smoker Specimen Testing Tobacco Tobacco Use Cessation Tobacco use Urine Woman Work base biobank cancer health disparity cancer prevention cigarette smoking design effective intervention men neonate novel preference pregnant programs tobacco exposure

项目摘要

Biomarker Feedback to Motivate Tobacco Cessation in Pregnant Alaska Native Women Project Leader: Christi Patten, Ph.D. Mayo Clinic Rochester MN Project Summary: Developing effective tobacco cessation inten/entions during pregnancy for American Indian and Alaska Native people is a national priority and will contribute to the U.S. public health objective of reducing tobaccorelated cancer health disparities. The proposed project builds on our successful partnership with the Alaska Native community and previous work with Alaska Native pregnant women. We propose to develop and test a novel biomarker feedback intervention relating cotinine levels in the urine of pregnant women with the woman and infant's likely exposure to the tobacco specific nitrosamine and carcinogen 4-(methylnitrosamino)-1 -(3-pyridyl)-1-butanone) (NNK). This 5-year project will be conducted in three phases. In Phase 1 we will utilize a non-randomized, clinical observational trial to examine biomarkers of nicotine and carcinogen exposure (urine cotinine and total NNAL [a metabolite of NNK], respectively) among 150 maternal-infant pairs with assessments conducted during pregnancy and at delivery. In Phase 2, we will obtain qualitative feedback on the findings from Phase 1 through individual interviews conducted with 32 women who use tobacco to develop the biomarker feedback intervention messages. Phase 3 will consist of a formative evaluation of the biomarker feedback intervention with 80 pregnant women using a two-group randomized design to assess the intervention's feasibility and acceptability, and the biochemically confirmed abstinence rate at the end of pregnancy. All phases of the project will be guided by a Community Advisory Committee. Each phase is an important step to advance our understanding of the potential for biomarker feedback as a strategy to help Alaska Native pregnant women quit tobacco use. The potential reach of the intervention is significant from a public health perspective as over 600 tobacco users deliver each year at the Alaska Native Medical Center in Anchorage where the proposed project will take place. Developing effective interventions for tobacco cessation during pregnancy is important to reduce adverse health consequences for the mother and neonate and future risk of tobacco-caused cancers.

生物标志物反馈以激励怀孕的烟草戒烟阿拉斯加土著妇女项目负责人：克里斯蒂·帕滕（Christi Patten）博士梅奥诊所罗切斯特项目摘要：为美洲印第安人和阿拉斯加土著人民在怀孕期间开发有效的烟草戒烟进程是国家的重中之重，将有助于美国公共卫生的目标，以减少毒品癌症的癌症健康差异。拟议的项目建立在我们与阿拉斯加本土社区的成功合作以及与阿拉斯加本地孕妇的先前合作的基础上。我们建议开发和测试一种新型的生物标志物反馈干预措施，该干预措施与孕妇的尿液中的可替宁水平有关妇女和婴儿可能暴露于烟草特异性硝基胺和致癌物4-（甲基硝基氨基氨基）-1-（3-吡啶基）-1-叔丁酮）（NNK）。这个5年的项目将分为三个阶段。在第1阶段中，我们将利用非随机的临床观察试验来检查150个产妇对尼古丁和致癌物暴露（分别为NNK的代谢产物）的生物标志物（分别为NNK的代谢产物），并在怀孕期间和递送过程中进行评估。在第2阶段，我们将通过与32名使用烟草来开发生物标志物反馈干预信息的女性进行的个人访谈获得定性反馈。第3阶段将包括对生物标志物反馈干预与80位孕妇的形成性评估，使用两组随机设计来评估干预措施的可行性和可接受性，以及在怀孕结束时生化确认的节制率。该项目的所有阶段将由社区咨询委员会指导。每个阶段都是促进我们对生物标志物反馈潜力的理解作为帮助阿拉斯加本地孕妇退出烟草使用的策略的重要步骤。从公共卫生的角度来看，干预措施的潜在影响很大，因为每年有600多名烟草用户在安克雷奇的阿拉斯加本地医疗中心提供，该项目将在此进行。在怀孕期间制定有效的烟草戒烟干预措施对于减少母亲和新生儿的不良健康后果和未来烟草引起的癌症的风险很重要。